All In MedTech

Device Trial Radar · NCT03733730

Post Approval Study of the AcrySof® IQ ReSTOR® Toric IOLs

Last checked: Nov 20, 2026Latest source record: Nov 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

2,449

Actual

Start

Nov 27, 2018

Primary completion

Oct 14, 2022

Study completion Oct 14, 2022

Sponsor

Lead sponsor
Alcon ResearchNot on our public-company list
Sponsor type
Industry
First posted
Nov 7, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multicenter, post-approval active surveillance study. The purpose of this study is to report the rate of post-surgical intraocular inflammation (based upon a specified case definition) reported within a 180-day post-surgical period following attempted implantation of an ACRYSOF IQ RESTOR Toric or ACRYSOF IQ RESTOR IOL in the US.

Conditions

  • Aphakia
  • Presbyopia
  • Astigmatism

Interventions

  • ACRYSOF IQ RESTOR +3.0 Multifocal Toric IOLDevice

    Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision, reduction of residual cylinder and increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.

  • ACRYSOF IQ RESTOR +2.5 D Multifocal Toric IOLDevice

    Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision, reduction of residual cylinder and increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.

  • ACRYSOF IQ RESTOR +2.5 D Multifocal IOLDevice

    Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision with increased spectacle independence. IOLs are implantable medical devices and are intended for long term use over the lifetime of the cataract subject.

  • Cataract SurgeryProcedure

    Routine small incision cataract surgery with IOL implantation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Eyes With Post-Surgical Intraocular Inflammation - By Eye - Cohort 2Time frame: Day 90 to 180 post implantation, each eye. The second eye was implanted within 20 days of the first eye.
  2. Rate of Eyes With Post-Surgical Intraocular Inflammation - Overall Eyes - Cohort 2Time frame: Day 90 to 180 post implantation, each eye. The second eye was implanted within 20 days of the first eye.

Locations

38 sites in 2 countries. Site status is shown where the registry gives one.

  • Trinity Research Group

    Dothan, Alabama

  • Eye Doctors of Arizona

    Phoenix, Arizona

  • InSight Vision Center

    Fresno, California

35 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.